These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 12749507

  • 1. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.
    Martin PD, Dane AL, Schneck DW, Warwick MJ.
    Clin Ther; 2003 Feb; 25(2):459-71. PubMed ID: 12749507
    [Abstract] [Full Text] [Related]

  • 2. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers.
    Martin PD, Kemp J, Dane AL, Warwick MJ, Schneck DW.
    J Clin Pharmacol; 2002 Dec; 42(12):1352-7. PubMed ID: 12463730
    [Abstract] [Full Text] [Related]

  • 3. Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics.
    Jones MR, Baker BA, Mathew P.
    Clin Pharmacokinet; 2004 Dec; 43(13):943-50. PubMed ID: 15509187
    [Abstract] [Full Text] [Related]

  • 4. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers.
    Martin PD, Warwick MJ, Dane AL, Cantarini MV.
    Clin Ther; 2003 Aug; 25(8):2215-24. PubMed ID: 14512129
    [Abstract] [Full Text] [Related]

  • 5. Effect of itraconazole on the pharmacokinetics of rosuvastatin.
    Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV.
    Clin Pharmacol Ther; 2003 Apr; 73(4):322-9. PubMed ID: 12709722
    [Abstract] [Full Text] [Related]

  • 6. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC, Davidson MH, Kelly MT, Setze CM.
    Am J Cardiovasc Drugs; 2012 Apr 01; 12(2):117-25. PubMed ID: 22263674
    [Abstract] [Full Text] [Related]

  • 7. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor.
    Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ.
    J Clin Pharmacol; 2002 Oct 01; 42(10):1116-21. PubMed ID: 12362926
    [Abstract] [Full Text] [Related]

  • 8. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.
    Martin PD, Warwick MJ, Dane AL, Brindley C, Short T.
    Clin Ther; 2003 Oct 01; 25(10):2553-63. PubMed ID: 14667956
    [Abstract] [Full Text] [Related]

  • 9. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
    Godfrey AR, Digiacinto J, Davis MW.
    Clin Ther; 2011 Jun 01; 33(6):766-75. PubMed ID: 21704241
    [Abstract] [Full Text] [Related]

  • 10. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.
    Martin PD, Mitchell PD, Schneck DW.
    Br J Clin Pharmacol; 2002 Nov 01; 54(5):472-7. PubMed ID: 12445025
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study.
    Li Y, Jiang X, Lan K, Zhang R, Li X, Jiang Q.
    Clin Ther; 2007 Oct 01; 29(10):2194-203. PubMed ID: 18042475
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
    Roth EM, Rosenson RS, Carlson DM, Fukumoto SM, Setze CM, Blasetto JW, Khurmi NS, Stolzenbach JC, Williams LA.
    Cardiovasc Drugs Ther; 2010 Dec 01; 24(5-6):421-8. PubMed ID: 20953684
    [Abstract] [Full Text] [Related]

  • 13. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.
    Bergman AJ, Murphy G, Burke J, Zhao JJ, Valesky R, Liu L, Lasseter KC, He W, Prueksaritanont T, Qiu Y, Hartford A, Vega JM, Paolini JF.
    J Clin Pharmacol; 2004 Sep 01; 44(9):1054-62. PubMed ID: 15317833
    [Abstract] [Full Text] [Related]

  • 14. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin.
    Samineni D, Desai PB, Sallans L, Fichtenbaum CJ.
    J Clin Pharmacol; 2012 Jun 01; 52(6):922-31. PubMed ID: 21712498
    [Abstract] [Full Text] [Related]

  • 15. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans.
    Zhu T, Awni WM, Hosmane B, Kelly MT, Sleep DJ, Stolzenbach JC, Wan K, Chira TO, Pradhan RS.
    J Clin Pharmacol; 2009 Jan 01; 49(1):63-71. PubMed ID: 18952910
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
    Kulmatycki K, Hanna I, Meyers D, Salunke A, Movva A, Majumdar T, Natrillo A, Vapurcuyan A, Rebello S, Sunkara G, Chen J.
    Int J Clin Pharmacol Ther; 2015 May 01; 53(5):345-55. PubMed ID: 25740267
    [Abstract] [Full Text] [Related]

  • 17. Lack of an Effect of Ritonavir Alone and Lopinavir-Ritonavir on the Pharmacokinetics of Fenofibric Acid in Healthy Volunteers.
    Gordon LA, Malati CY, Hadigan C, McLaughlin M, Alfaro RM, Calderón MM, Kovacs JA, Penzak SR.
    Pharmacotherapy; 2016 Jan 01; 36(1):49-56. PubMed ID: 26799348
    [Abstract] [Full Text] [Related]

  • 18. The effect of fluconazole on the pharmacokinetics of rosuvastatin.
    Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV.
    Eur J Clin Pharmacol; 2002 Nov 01; 58(8):527-31. PubMed ID: 12451430
    [Abstract] [Full Text] [Related]

  • 19. The effect of erythromycin on the pharmacokinetics of rosuvastatin.
    Cooper KJ, Martin PD, Dane AL, Warwick MJ, Raza A, Schneck DW.
    Eur J Clin Pharmacol; 2003 May 01; 59(1):51-6. PubMed ID: 12682802
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
    Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC.
    Am J Cardiovasc Drugs; 2010 May 01; 10(2):73-84. PubMed ID: 20136164
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.